PW Medtech Group Limited — Earnings Release 2014

Dec 2, 2014

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED 普 華 和 順 集 團 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

PROFIT ALERT

The Board would like to inform the shareholders of the Company and potential investors that based on the preliminary review of the unaudited management accounts of the Group and other information currently available, the Group expects the unaudited adjusted net profit for the year ending 31 December 2014 to increase by over 45% as compared to the Group’s unaudited adjusted net profit of approximately RMB140.7 million for the year ended 31 December 2013.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by PW Medtech Group Limited (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) in accordance with Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) concerning disclosure of inside information and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors (the ‘‘Board’’) of the Company wishes to inform the shareholders (the ‘‘Shareholders’’) and potential investors of the Company that based on the preliminary review of the unaudited management accounts of the Group and other information currently available, the Group expects the unaudited adjusted net profit (which is derived by excluding non-operational and one-off items which are expected to mainly comprise share-based compensation expenses and cost for merger and acquisition) for the year ending 31 December 2014 (the ‘‘FY2014’’) to increase by over 45% as compared to the Group’s unaudited adjusted net profit of approximately RMB140.7 million for the year ended 31 December 2013, which was derived by excluding non-operational and one-off items comprising share-based compensation expenses and listing-related expenses from profit for the year. Noting a slowdown in the growth of the general medical device market comparing to the expectation due to the challenging economic environment, the Board is nevertheless confident about the long term growth of the Group’s business. The Board also took into account the unaudited adjusted net profit contributed from the regenerative medical biomaterial business of Beijing Tianxinfu Medical Appliance Co., Ltd, which became the Company’s wholly-owned subsidiary in early August 2014.

– 1 –

The Company is still in the process of finalizing the audited consolidated final results of the Group for the FY2014, and the information set out in this announcement is only a preliminary assessment by the Board which has not been reviewed nor audited by the Company’s auditors and is subject to possible adjustments following further internal review. Further, the information in this announcement is not based on any figure or information which has been reviewed by the Company’s auditors or audit committee. The finalised audited consolidated final results of the Group and other related details will be disclosed in the 2014 final results announcement and annual report to be published by the Company in due course.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board PW Medtech Group Limited Lin Junshan Chairman

Hong Kong, 2 December 2014

As at the date of this announcement, the Board comprises one executive director, namely, Mr. JIANG Liwei; three nonexecutive directors, namely, Mr. LIN Junshan, Ms. Yue’e ZHANG and Mr. FENG Dai; and three independent non-executive directors, namely, Mr. ZHANG Xingdong, Mr. CHEN Geng and Mr. WANG Xiaogang.

– 2 –